Compare PAY & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAY | IRON |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2021 | 2020 |
| Metric | PAY | IRON |
|---|---|---|
| Price | $21.84 | $69.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $36.29 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 784.6K | 384.6K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.57 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $1,196,507,000.00 | N/A |
| Revenue This Year | $18.60 | N/A |
| Revenue Next Year | $18.89 | $283.52 |
| P/E Ratio | $132.75 | ★ N/A |
| Revenue Growth | ★ 37.25 | N/A |
| 52 Week Low | $20.33 | $40.00 |
| 52 Week High | $39.38 | $99.50 |
| Indicator | PAY | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 54.12 |
| Support Level | $20.33 | $64.48 |
| Resistance Level | $26.11 | $71.85 |
| Average True Range (ATR) | 0.91 | 3.26 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 40.99 | 64.61 |
Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers through a Software-as-a-Service (SaaS), secure, omni-channel technology platform. The platform integrates with a biller's financial and operational systems to provide secure and flexible processing of payments, including credit cards, debit cards, eChecks, and digital wallets, across multiple channels such as online, mobile, IVR, call centers, chatbots, and voice-based assistants. The company generates the majority of its revenue from payment transaction fees processed through its platform. Geographically, it derives the maximum revenue from the United States.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.